Results 131 to 140 of about 13,718 (263)
Effect of public health expenditure on maternal mortality ratio in the West African Economic and Monetary Union. [PDF]
Boundioa J, Thiombiano N.
europepmc +1 more source
ABSTRACT Self‐determination has been assessed as an internal psychological construct. External factors may also affect self‐determination, but opportunities to make choices and decisions remain understudied. We developed and evaluated the AASPIRE‐Choices and Decisions Scale (AASPIRE‐CDS), a new measure of autistic adults' opportunities to make choices ...
So Yoon Kim +14 more
wiley +1 more source
A sustainable business ecosystem: a case study demonstrating biochar's potential
Abstract The need for renewable, climate‐friendly resources has become urgent as legislators worldwide have sought to find ways to cut emissions while ensuring resource security for consumers. The use of biochar could help to achieve these goals. This study examines the current state of commercial biochar production and the maturity of the related ...
Juuso Kivijakola +4 more
wiley +1 more source
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden +3 more
wiley +1 more source
Cohort Profile: Kinship, nuptiality and child well-being in Africa-the JAMO study. [PDF]
Madhavan S +10 more
europepmc +1 more source
Zuranolone: A case study in (regulatory) rush to judgement?
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove +4 more
wiley +1 more source

